Neuland Laboratories Limited reported a stellar financial performance for the fiscal year ended March 31, 2026, with total revenue reaching ₹2,053.15 crore on a consolidated basis. The company also announced a final dividend of ₹34 per share and a significant capacity enhancement project at its Unit 1 facility in Telangana, requiring an investment of ₹143.4 crore to meet rising customer demand. Additionally, Dr. Mauricio Futran has been appointed as an Additional Director.
Financial Highlights
Neuland Laboratories has demonstrated strong growth for the full fiscal year ended March 31, 2026. The company achieved a consolidated total income of ₹2,053.15 crore, marking a substantial increase over the previous year. Profit for the period surged to ₹363.99 crore, reflecting the company’s operational efficiency. For the final quarter (Q4) ending March 31, 2026, the company reported revenue of ₹776.25 crore and a profit of ₹212.67 crore.
Dividend Recommendation
Reflecting its strong financial health, the Board of Directors has recommended a final dividend of ₹34 per equity share, representing a 340% payout on the face value of ₹10 per share. This recommendation is subject to shareholder approval at the upcoming 42nd Annual General Meeting scheduled for August 4, 2026.
Strategic Capacity Enhancement
To support growing market demand, the company is embarking on an expansion at its Unit 1 facility located in Bonthapally Village, Telangana. The project involves an addition of 120.5 KL to the existing 256 KL capacity. This investment of ₹143.4 crore will be financed through a mix of internal accruals and borrowings, with construction expected to be completed within 12 to 18 months.
Leadership Appointment
The company has strengthened its board with the appointment of Dr. Mauricio Futran as an Additional Director, categorized as a Non-Executive Non-Independent member, effective May 12, 2026. Dr. Futran brings over 40 years of extensive expertise in chemical engineering and manufacturing, having previously served at major global pharmaceutical organizations.
Source: BSE
